CJC-1295 No DAC

Περιγραφή

CJC-1295 No DAC, commonly referred to as Modified GRF (1-29) or CJC-1295 without Drug Affinity Complex (DAC), is a synthetic tetrasubstituted analog of growth hormone-releasing hormone (GHRH 1-29). This peptide is designed to stimulate the pituitary gland to release endogenous growth hormone (GH) in a pulsatile, more natural manner compared to longer-acting versions. Without the DAC modification, it has a relatively short half-life of approximately 30 minutes to 1-2 hours, leading to brief but potent GH pulses that closely mimic the body’s physiological secretion patterns—typically administered multiple times daily (e.g., morning, post-workout, and bedtime) via subcutaneous injection to optimize benefits. Research and anecdotal reports highlight potential advantages including increased lean muscle mass, accelerated muscle repair and recovery from injuries or intense training, enhanced fat metabolism and body composition improvements, better sleep quality, increased energy levels, improved bone density, and support for overall metabolic health. It is frequently researched or used in stacks with growth hormone secretagogues like Ipamorelin to amplify GH release without significantly elevating prolactin or cortisol, often at combined doses of 100-300 mcg per injection. Common research protocols involve 100-200 mcg per dose, 2-3 times daily, with cycles lasting 8-12 weeks followed by breaks to prevent desensitization. While preclinical and limited human observational data suggest these regenerative and performance-enhancing effects, CJC-1295 No DAC is not FDA-approved for any therapeutic or medical use as of 2026—it remains an investigational research peptide, classified in certain regulatory contexts as presenting safety risks for human compounding or use, with no large-scale randomized clinical trials confirming long-term efficacy or safety in humans. Side effects reported in user experiences are generally mild and may include injection-site irritation, temporary water retention, headaches, flushing, fatigue, dizziness, or flu-like symptoms, though more serious concerns could involve potential hormonal imbalances, insulin sensitivity changes, or unknown long-term risks like joint discomfort from elevated GH/IGF-1. It is prohibited by WADA for athletes and should never be used without supervision from a qualified healthcare provider experienced in peptides, as self-administration carries risks of contamination, improper dosing, adverse reactions, or legal issues. Prioritize evidence-based approaches for fitness, recovery, or anti-aging goals—consult a professional to assess suitability, source from reputable compounding pharmacies if considered under guidance, and stay informed on evolving research or regulatory status. CJC-1295 No DAC is not a substitute for proven medical treatments or lifestyle interventions.